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Abstract
Objective
COVID-19 is a novel infectious disease with a broad spectrum of clinical severity. Patients with 
systemic vasculitis have an increased risk of serious infections and so may be at risk of severe 
outcomes following COVID-19. It is important to establish the risk factors for severe COVID-19 
outcomes in these patients, including the impact of immunosuppressive therapies. 
Methods
A multi-centre cohort was developed through the participation of centres affiliated with national 
UK and Ireland vasculitis registries. Clinical characteristics and outcomes were described. 
Logistic regression was used to evaluate associations between potential risk factors and severe 
COVID-19 outcome, defined as a requirement for advanced oxygen therapy, invasive ventilation, 
or death.
Results
Sixty-five cases of patients with systemic vasculitis who developed COVID-19 were reported 
(median age 70 years, 49% female) of whom 25 (38%) experienced a severe outcome. Most 
cases (55/65, 85%) had ANCA-associated vasculitis (AAV). Almost all patients required 
hospitalization (59/65, 91%), 7 patients (11%) were admitted to intensive care and 18 patients 
(28%) died. Background glucocorticoid therapy was associated with severe outcome (adjusted 
odds ratio [aOR] 3.7 (1.1-14.9, p=0.047)) as was comorbid respiratory disease (aOR 7.5 (1.9-
38.2, p=0.006)). Vasculitis disease activity and non-glucocorticoid immunosuppression were not 
associated with severe outcome.
Conclusion
In patients with systemic vasculitis, glucocorticoid use at presentation and comorbid respiratory 
disease were associated with severe outcomes in COVID-19. These data can inform clinical 
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Introduction
Coronavirus disease 2019 (COVID-19) is a novel, multi-system infectious disease caused by 
severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). COVID-19 causes a broad 
spectrum of clinical severity (1), ranging from asymptomatic disease to severe respiratory failure 
and death. In March 2020 the World Health Organisation characterized COVID-19 as a global 
pandemic (2) prompting considerable concerns from health care systems globally about their 
resilience to manage this threat. Critical care service capacity was, and remains, a global priority.
Systemic vasculitis is a rare, multi-system autoimmune disorder. Compared to other rheumatic 
musculoskeletal diseases, it may result in major organ dysfunction and so is typically managed 
with more potent immunosuppression and higher doses of glucocorticoids in order to induce and 
maintain disease remission. While this therapeutic approach successfully manages vasculitis 
activity, glucocorticoid exposure contributes, in part, to the increased risk of infection in these 
patients (3,4).  Thus, although risk factors associated wth poor outcomes from COVID-19 in this 
population are unknown, there is an assumption that these patients are at high risk.   
The RECOVERY trial has demonstrated a benefit from moderate dose glucocorticoids in 
hospitalized general population patients with COVID-19 requiring supplemental oxygen or 
mechanical ventilation, but potential harm when used in milder disease (5). Given these 
paradoxical effects, it is unknown whether chronic background glucocorticoid exposure makes 
patients more susceptible to severe COVID-19 infection, or whether it might be protective. 
We report the results of a coordinated bi-national effort to identify the predictors of severe 
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Methods
Study design
A registry-based multi-centre cohort was designed to facilitate rapid real-world data capture. 
Centres affiliated with the UK and Ireland Vasculitis Registry (UKIVAS; www.ukivas.org/) and the 
Irish Rare Kidney Disease Registry (RKD; www.tcd.ie/medicine/thkc/research/rare.php) were 
invited to contribute. UKIVAS covers 89 sites; RKD covers 8 sites across Ireland. Participating 
centres represent both secondary and tertiary centres across the UK and Ireland resulting in a 
broad population sampling frame. A vasculitis-focused COVID-19 case report form (CRF) was 
developed, underpinned by standardized BioPortal ontologies (e.g. SNOMED CT) (6) and 
interoperable with other emerging datasets such as the COVID-19 Global Rheumatology Alliance 
(GRA) (7), thereby facilitating future international data linkage as the COVID-19 pandemic 
progresses. This enables compatibility of these data with the principles of the global GO-FAIR 
initiative (8). Additional modules of the UKIVAS and RKD webapps were developed to support 
data capture.
Study population
Patients were eligible for case submission if they had a diagnosis of systemic vasculitis and 
COVID-19 (laboratory, radiological or clinical). The diagnosis of vasculitis was determined by the 
local specialist clinician, as per the International Chapel Hill Consensus Nomenclature of 
Vasculitides (9). Recruitment commenced on 28 March 2020 and is ongoing. For this analysis, 
the final case was submitted on 31 July 2020. The population sampling frame consisted of 
individuals under the clinical care of sites associated with the UKIVAS and RKD registries. At the 
end of July 2020 there were 795 patients in the RKD registry and approximately 7400 patients in 
the UKIVAS registry, with 4 patients being enrolled in both. In the UK, the Health Research 
Authority decision tool determined that ethics approval was not required and the local sponsor 
confirmed the project as a service evaluation (R&D reference GN20RH165). RKD registry ethics 
approval was originally granted by the Tallaght University Hospital/St. James's Hospital Joint 
Research Ethics Committee (ref 2019-08 List 29 (07)). All RKD participants provided informed 
consent. Additional approvals were not required.
Study variables
Variables collected included potential predictors of severe outcome. The selection of predictive 
variables was informed by emerging risk factors for COVID-19 disease severity in other 
populations (10,11). These included age, sex, ethnicity, smoking status, comorbid conditions, 
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conditions, respiratory disease refers to non-vasculitis related lower respiratory tract disease, 
though it is possible that some patients had coexistent vasculitis related respiratory disease. 
Intravenous immunosuppressive therapy was considered to be ‘current’ if the assessing clinician 
determined that the therapy was likely to be exerting a biological effect at the time of COVID-19 
diagnosis, specific definitions were not provided. Vasculitis disease activity was determined 
according to global clinician assessment. Outcome data collected included complications, such 
as acute kidney injury (AKI), respiratory failure and vasopressor requirement, and death. To 
enable interoperability, the same standardized 1-8 graded outcome as the COVID-19 Global 
Rheumatology Alliance (GRA) was used (Supplementary Table 1) (10). A severe outcome was 
defined as a composite of requirement for advanced oxygen therapy (such as non-invasive 
ventilation or high-flow oxygen device), requirement for invasive ventilation or death. Dates of 
hospital and intensive care unit admission and discharge were collected in order to derive length 
of stay. Other variables were collected to characterize the clinical features of COVID-19 in 
patients with vasculitis. These included symptoms, laboratory tests and radiology results. 
Reporting clinicians were asked to indicate which of these variables contributed to diagnosis.
Statistical analysis
Continuous variables were described as median (IQR). Categorical variables were described as 
number and percentage (%). Association between various explanatory variables and the odds of 
severe outcome was determined. Unadjusted and age/sex adjusted logistic regression models 
were individually calculated for each explanatory variable and reported as odds ratios (OR), p-
values and 95% confidence intervals (95% CIs). The adjusted odds ratios (aOR) for age and sex 
were derived from a single logistic regression model which included age and sex only. Where a 
potential interaction could account for a positive finding, logistic regression modeling 
incorporating the explanatory and interacting variables was used.  Sensitivity analyses were 
performed where any effects may have been different in an important subgroup. Missing data 
were stated in the relevant tables. Statistical significance was set at 5%. R (version 4.0.2) was 
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Results
In total, 65 patients with an established diagnosis of systemic vasculitis who developed COVID-
19 were registered. Fifty-eight patients were submitted to UKIVAS and 7 were submitted to RKD, 
with no duplicate submissions.
Baseline Characteristics (Table 1)
Median age was 70 years (IQR 55-76) and 49% were female. The majority (55/65, 85%) had anti-
neutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV) (granulomatosis with 
polyangiitis (GPA): 24/55, 44%; microscopic polyangiitis (MPA): 25/55, 45% and eosinophilic 
granulomatosis with polyangiitis (EGPA): 6/55, 11%). The characteristics of AAV patients were 
broadly similar to the full cohort (data not shown). Thirty-two patients (49%) were assessed to 
have concurrent active disease. Fifteen patients (23%) were suspected to have contracted 
COVID-19 through a healthcare setting; of these, 9/15 (60%) had some degree of active 
vasculitis. In one case, COVID-19 was considered to have increased disease activity. For the 
remainder, COVID-19 was not perceived to have altered or induced disease activity. 
Forty-seven patients (72%) were diagnosed by PCR testing, 3 (5%) did not have PCR confirmed 
disease but had radiological evidence, 3 (5%) were diagnosed by clinical presentation only. Data 
on diagnostic testing were unknown/missing for 12 patients (18%). The characteristics of those 
diagnosed by PCR testing were broadly similar to the full cohort (data not shown).
Most patients were receiving background glucocorticoids (45/65, 69%) at the time of COVID-19 
diagnosis. Nineteen (29%) were receiving the equivalent of 5 mg prednisone or less, 26/65 (40%) 
were receiving more than 5 mg. For those on background glucocorticoid, the median dose was 
the equivalent of 7.5 mg prednisone daily (IQR 5-25 mg). Twenty-two (34%) and 10 (15%) were 
recently treated with rituximab and cyclophosphamide, respectively.
Symptom frequency (Figure 1)
The most common symptoms were dyspnoea (41/65, 63%), fever (38/65, 58%) and cough 
(37/65, 57%). Hemoptysis occurred in 3 individuals (5%) and epistaxis occurred in 3 individuals 
(5%) – of these, one patient had both epistaxis and haemoptysis. Of note, some of these patients 
had ongoing disease activity prior to COVID-19 diagnosis.
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Respiratory failure was the most commonly reported complication (35/65, 54%), followed by AKI 
(12/65, 18%) and secondary infection (10/65, 15%).
Clinical outcomes (Table 2)
Almost all patients required hospitalization (59/65, 91%); 7/65 (11%) were admitted to an 
intensive care unit (ICU) and 18/65 (28%) died. Median length of hospital stay for discharged 
patients was 11 days (IQR 5-27). A severe outcome was experienced by 25/65 (38%).
Predictors of severe outcome (Table 3)
Patients with comorbid respiratory disease were more likely to suffer a severe outcome than 
those without (aOR 7.5, 95% CI 1.9-38.2, p=0.006) as were those prescribed glucocorticoids 
(aOR 3.7, 95% CI 1.1-14.9, p=0.047). Glucocorticoid exposure remained a poor prognostic 
indicator even after adjusting for vasculitis disease activity (data not shown). A sensitivity analysis 
including only those with confirmed PCR diagnosis (n = 47) was performed which demonstrated 
effect sizes consistent with these findings, this was statistically significant for comorbid respiratory 
disease but not for glucocorticoid exposure (data not shown). A sensitivity analysis was also 
performed for individuals with AAV (n = 55) with a similar result. There was insufficient power to 
assess the association between glucocorticoid dose and poor outcome. Similarly there was 
insufficient power to assess for differences between common non-glucocorticoid 
immunosuppressive agents. Associations were not demonstrated for any demographics, other 
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Discussion
This multi-centre study reports the largest cohort of patients with systemic vasculitis developing 
COVID-19 to date. It identifies comorbid respiratory disease and background glucocorticoid 
therapy as significant predictors of a severe outcome, as defined by need for advanced oxygen 
therapy or invasive ventilation, or death. Routinely used non-glucocorticoid immunosuppressants, 
such as rituximab and cyclophosphamide were not associated with a severe outcome and neither 
was vasculitis disease activity. 
Glucocorticoids have pleotropic immunological effects and are generally considered risk factors 
for infections (12). Glucocorticoids at high dose have been associated with prolonged viral 
shedding, with a similar effect being observed in other coronaviruses (13,14). That 
glucocorticoids associate with worse COVID-19 disease is consistent with findings from across 
the rheumatic autoimmune spectrum, as reported by COVID-19 GRA (10). Our point estimate for 
the association of any glucocorticoid dose with severe outcome (OR 3.66; 95% CI 1.09-14.9) was 
comparable to the COVID-19 GRA study’s evaluation of steroids at or above the equivalent of 10 
mg prednisolone per day (OR 2.05; 1.06 to 3.96). The confidence interval for this finding is 
relatively wide and therefore it remains to be determined if there is a dose threshold at which risk 
commenses. This association between glucocorticoids and severe outcome may appear to 
conflict with findings from the RECOVERY trial. This trial found that low-dose dexamethasone 
had a substantial survival benefit in individuals hospitalised with COVID-19. However, the groups 
that benefited in RECOVERY were those requiring supplemental oxygen with the greatest benefit 
being derived in those requiring mechanical ventilation. In fact, the point estimate for those not 
requiring oxygen suggested that glucorticoids could be associated with increased mortality, 
though this was not a statistically significant finding (5). Therefore, prior to requiring oxygen, it 
may be that glucorticoids are deleterious, as observed in this and other studies of autoimmune 
disease (15). Our finding that co-morbid respiratory disease (most commonly chronic obstructive 
pulmonary disease, asthma and interstitial lung disease) was associated with severe disease 
outcomes was consistent with a recent general population meta-analysis (16). Enhanced 
respiratory tract ACE2 expression, the principal binding site for COVID-19 cell entry, among 
some patients with chronic lung disease is a possible explanation for this association (10). 
Consistent with the COVID-19 GRA report, we did not find an association with adverse disease 
outcomes for other immunosuppressive agents (17). This is reassuring since current guidance 
emphasises the importance of maintaining immunosuppression therapy among uninfected 
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This cohort represents a severely affected group, as reflected by the very high proportion of 
hospitalisation (91%).  The mortality rate of 28% is similar to that reported in the largest UK study 
of hospitalised patients carried out by the ISARIC WHO Clinical Characterisation Protocol UK 
group in which 26% died (18). Age, sex and symptom distribution were also broadly similar to the 
ISARIC WHO report. The most common symptoms, in that cohort and ours, were those which 
have been most prominent in the case definition: breathlessness, fever and cough. Both active 
pulmonary vasculitis and COVID-19 are recognised causes of haemoptysis (18,19). In the 
ISARIC WHO UK group 3.5% had this symptom, 3 (4.8%) patients experienced this symptom in 
our cohort. None were thought to have diffuse alveolar haemorrhage, as judged by the 
responding clinician. Differentiating COVID-19 from active pulmonary vasculitis remains a 
challenge and indeed these presentations may coexist. Ensuring these diagnoses are considered 
where a patient with vasculitis presents with haemoptysis remains of high importance. 
A large proportion (49%) of patients had concurrent active vasculitis. Of these a considerable 
proportion was suspected to have acquired COVID-19 from a healthcare setting. Notably, the 
onset of vasculitis disease activity preceded COVID-19 infection in almost all cases. However, it 
is unknown if COVID-19 may trigger vasculitis activity in the longer term. The emergence of 
paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 (PIMS-
TS), a condition bearing strong similarities to Kawasaki disease, is a potential example of SARS-
CoV-2 triggering autoimmune vasculitis, though the pathogenesis is currently not understood 
(20). Our study did not find evidence of vasculitis being triggered in the short-term. Longitudinal 
studies will seek to address this question. The prevalence of active disease in this cohort is 
higher than expected – previous cross-sectional UK studies have reported disease activity 
prevalence at approximately 20% (21). Although disease activity was not associated with worse 
outcome, it may be that patients with unstable disease are more vulnerable to contracting 
COVID-19. Physician or patient-led reduction in immunosuppressive treatment, in a bid to limit 
the impact of COVID-19, is another potential reason accounting for a high proportion of disease 
activity. Due to study design, our data are limited in the extent to which they can inform this 
question.
Ascertainment bias is likely to have affected this study. Given that most patients were 
hospitalized, it is likely that patients with milder disease were not identified. The number of PCR 
diagnosed patients in our study as a proportion of the combined UKIVAS and RKD populations 
was similar to the proportion of UK cases relative to the UK population for a comparable time 
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with vasculitis may have been more likely to have contracted COVID-19 due to risk factors such 
as immunosuppressive therapy and need to attend healthcare facilities, therefore ascertainment 
bias remains possible. There was a high preponderance of small vessel vasculitis (SVV) in this 
study compared to giant cell arteritis (GCA). Although more common, individuals with GCA are 
typically older and may have adopted stricter self-isolation restrictions (as per national guidance). 
In addition, SVV may have predominated due to a disproportionate number of renal units 
compared to rheumatology centres represented in UKIVAS. Due to a large majority of patient in 
this study having SVV, the extent to which the findings of this study can be generalised to other 
vasculitides is limited. Other limitations of this study include relative lack of power. As a result, our 
analyses may not detect some clinically significant effects and conversely the risk of spurious 
findings are higher. Similarly, due to the limited number of events, our ability to control for multiple 
potential confounding factors was limited. Due to the heterogeneous immunobiology, phenotypes 
and management approaches of systemic vasculitis it is possible that individual disorders may 
incur different risks, due to insufficient power we were limited in the extent to which this could be 
examined.
This study is the first to describe a cohort of vasculitis patients with COVID-19. The clinical 
presentation of COVID-19 was similar to descriptions in large series of patients without 
autoimmune disease. Glucocorticoids were associated with increased risk of severe outcome, but 
other immunosuppressants were not.  Individuals with autoimmune disease have been 
considered vulnerable during the COVID-19 pandemic and many governments have instructed 
that they adhere to exceptional social isolation restrictions. While patients with systemic vasculitis 
remain at higher risk, these data indicate that some patients may not need to face similar 
restrictions in the future, if other known risk factors are absent.  Conversely, patients who are 
receiving background corticosteroids or have co-morbid respiratory disease, should be closely 
monitored when presenting with COVID-19 since their risk of progression to a severe state 
appears higher (11). This study largely describes a cohort of hospitalised patients and so more 
likely reflects severe COVID-19 disease. Future work should seek to establish risk factors for 
severe disease in a wider population. Comparisons with controls who did not contract COVID-19 
would allow assessment of incidence and risk factors for contracting COVID-19.
Together with reports of other cohorts exposed to immunosuppressant medication, these data 
could inform future public health guidance for individuals with autoimmune disease. These data 
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combine international efforts to allow for greater power to assess the factors which impact upon 
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Table 1: Baseline characteristics (n = 65)
Age; median (IQR) 70 (55-76)





Not stated 6 (9.2)
(Missing) 5 (7.7)




(Unknown / missing) 21 (32.3)
Comorbid conditions; n (%)
Vasculitis diagnosis; n (%)
GPA (or PR3 AAV) 24 (36.9)
MPA (or MPO AAV) 25 (38.5)
EGPA 6 (9.2)
LVV 2 (3.1)






CV disease 17 (26.2)
Respiratory disease** 13 (20.0)
Renal Disease 30 (46.2)
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Organ transplant 3 (4.6)
Vasculitis – active disease; n (%) 32 (49.2)
Vasculitis – disease duration (years); median (IQR) 2.2 (0.76 – 6.8)
Current immunosuppressive therapy, n (%)
Any immunosuppressive therapy 56 (86.2)
Any immunosuppressive therapy and on glucocorticoids 43 (66.2)
Azathioprine 12 (18.5)
Glucocorticoid (any dose) 45 (69.2)
Prednisone 1.0-5.0 mg daily 19 (29.2)
Prednisone 5.1 mg daily or greater 26 (40.0)











(ACEI / ARB / NSAID: unknown / missing) 5 (7.7)
Laboratory tests (median, IQR)
Creatinine (μmol/L)**** 127 (69 – 204)
C-reactive protein (mg/L) 99 (44 – 149)




Symptoms only 3 (4.6)
(Method unknown / missing) 12 (18.5)
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** Respiratory disease refers to non-vasculitis related lower respiratory tract disease, though it is 
possible that some patients had coexistent vasculitis related respiratory disease.
*** includes 13 patients on haemodialysis, 3 kidney transplant recipients and 1 patient with 
sustained chronic kidney disease stage 5.
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Table 2: Outcomes (n = 65)




(Unknown / missing) 9 (13.8)
Graded outcome; n (%)
1. Not hospitalized, no limitations on activities 2 (3.1)
2. Not hospitalized, limitation on activities 3 (4.6)
3. Hospitalized, not requiring supplemental oxygen 9 (13.8)
4. Hospitalized, requiring supplemental oxygen 25 (38.5)
5. Hospitalized, on non-invasive ventilation or high flow 
oxygen devices 4 (6.2)
6. Hospitalized, on invasive mechanical ventilation or 
ECMO 3 (4.6)
7. Death 18 (27.7)
(Missing) 1 (1.5)
Length of stay (days; median (IQR)) 11 (5 - 27)
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Table 3: Unadjusted and adjusted odds ratios for various potential risk factors and association 
with severe outcome*












Age - 1.01  (0.98-
1.05)




GPA (reference: not 
GPA)





MPA (reference: not 
MPA)
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(any; 




No prednisone 4 / 18 (22) ref ref
Prednisone (any 
dose)

















(reference: not on 
azathioprine)













Rituximab (reference:  
not on rituximab)





* A severe outcome was defined as a composite of requirement for advanced oxygen therapy 
(such as non-invasive ventilation or high-flow oxygen device), requirement for invasive ventilation 
or death.
** P values for adjusted models. A separate logistic regression model including sex and age as a 
continuous variable was calculated for each explanatory variable. The adjusted models for age 
and sex were derived from a single logistic regression model which included sex and age as a 
continuous variable.
*** Respiratory disease refers to non-vasculitis related lower respiratory tract disease, though it is 
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Figure legends
Figure 1 – Symptoms at initial presentation -  frequency
Figure 2 – Complication frequency
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